Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 591

2.

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

Lage MJ, Fabunmi R, Boye KS, Misurski DA.

Adv Ther. 2009 Feb;26(2):217-29. doi: 10.1007/s12325-009-0002-0. Epub 2009 Feb 14.

PMID:
19219409
3.

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.

J Med Econ. 2012;15(6):1039-50. doi: 10.3111/13696998.2012.688903. Epub 2012 May 24.

PMID:
22533526
4.
5.

Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.

Suehs BT, Sikirica V, Mudumby P, Dufour R, Patel NC.

J Manag Care Spec Pharm. 2015 Sep;21(9):793-802, 802a-802i.

6.

Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.

Bell K, Parasuraman S, Raju A, Shah M, Graham J, Denno M.

J Manag Care Spec Pharm. 2015 Mar;21(3):220-8a.

8.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

9.

Dalfampridine prior authorization program: a cohort study.

Gleason PP, Phillips J, Fenrick BA, Delgado-Riley A, Starner CI.

J Manag Care Pharm. 2013 Jan-Feb;19(1):18-25.

10.

Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.

Martin C, Odell K, Cappelleri JC, Bancroft T, Halpern R, Sadosky A.

J Manag Care Spec Pharm. 2016 Feb;22(2):132-44. doi: 10.18553/jmcp.2016.15180. Epub 2015 Dec 14.

11.
12.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

13.

Benefit restrictions and gout treatment.

Wang SM, Aranda GA Jr, Gao S, Patel BV.

J Manag Care Pharm. 2013 Nov-Dec;19(9):773-82.

14.
15.
16.

Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.

DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J.

Adv Ther. 2014 Feb;31(2):202-16. doi: 10.1007/s12325-014-0098-8. Epub 2014 Jan 30.

17.

Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.

Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.

Adv Ther. 2010 Apr;27(4):223-32. doi: 10.1007/s12325-010-0024-7. Epub 2010 May 10.

PMID:
20464538
18.

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.

J Manag Care Pharm. 2008 Jun;14(5):451-61.

19.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
20.

Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.

Yeaw J, Lee WC, Aagren M, Christensen T.

J Manag Care Pharm. 2012 Jan-Feb;18(1):21-32.

Items per page

Supplemental Content

Write to the Help Desk